The Birlinn HH Panel G203 is intended for in vitro use as a quality control to monitor the analytical performance of test systems used in the qualitative detection of the HFE H63D, S65C and C282Y variants most commonly associated with hereditary hemochromatosis (HH). The Birlinn HH Panel G203 consists of synthetic HFE DNA encompassing H63D, S65C and C282Y variants mixed with wildtype (WT) DNA, suspended in a non-infectious buffer with stabilizers to create genotypes associated with HH. The Birlinn HH Panel G203 is provided as a non-extractable control with copy numbers of HFE DNA similar to that of extracted human whole blood samples. Three (3) of the tubes contain HFE genotypes H63D HET, S65C WT, C282Y HET. The other 3 tubes contain HFE genotypes H63D WT, S65C MUT, C282Y WT. Birlinn HH Panel G203 DNA has been bi-directionally sequenced to validate the presence of mutant or wild type HFE sequence.